Navigation Links
Kosan Announces Third Quarter 2007 Financial Results
Date:11/8/2007

President and Chief Executive Officer. "We believe that the growing body of positive clinical data that we have generated in our clinical trials to date, combined with development and regulatory strategies that are being successfully implemented in all of our clinical programs and the commercial potential of our Hsp90 and epothilone programs, position Kosan as an attractive investment opportunity."

Third Quarter 2007 Highlights

-- Kosan reached a binding agreement with the U.S. Food and Drug

Administration (FDA) on the design of Kosan's TIME-1 clinical trial, a

pivotal Phase 3 trial of Kosan's Hsp90 inhibitor tanespimycin as a

treatment for patients with multiple myeloma, through a Special

Protocol Assessment (SPA) process with the FDA. Kosan also completed

the "Scientific Advice" process with the centralized European Medicines

Agency (EMEA) for TIME-1.

-- At the 2007 Breast Cancer Symposium of the American Society of Clinical

Oncology (ASCO), Kosan presented updated data from a Phase 1 clinical

trial showing that Kosan's Hsp90 inhibitor alvespimycin demonstrated

antitumor activity and tolerability in combination with trastuzumab

(Herceptin(R)), with clinical benefit observed in 42% of evaluable

patients (8 of 19 evaluable) with HER2-positive metastatic breast

cancer.

-- Pfizer Inc. initiated a Phase 1 clinical trial designed to test the

safety, tolerability and pharmacokinetics of motilin receptor agonist

KOS-2187, a selective and potent motilin receptor agonist being

developed for the treatment of gastroesophageal reflux disease (GERD)

and potentially other gastrointestinal disorders.

-- Kosan completed preparations and is planning to initiate later this

quarter a Phase 2 clinical trial of alvespimycin in patients with

newly-diagnosed HER2-positive metastatic breast cance
'/>"/>

SOURCE Kosan Biosciences Incorporated
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related biology technology :

1. Kosan Biosciences to Present at the Bear Stearns 20th Annual Healthcare Conference
2. Kosan Biosciences to Present at the 2007 UBS Global Life Sciences Conference
3. Kosan Biosciences to Present at the Biotechnology Industry Organization Investor Forum
4. Kosan Biosciences to Host Research & Development Day on October 31, 2007
5. Kosan to Reacquire Epothilone Program From Roche
6. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
7. YM BIOSCIENCES ANNOUNCES COMPLIANCE WITH AIM RULE 26
8. Emisphere Technologies, Inc. Announces Pricing of Registered Direct Offering
9. BioLife Solutions Announces Exclusive CryoStor(TM) Supply Agreement With the New England Cryogenic Center, Inc.
10. Carrington Announces Nasdaq Communication; Prepares for Shares to Be Quoted on the OTC Bulletin Board and Pink Sheets
11. China Kangtai Cactus Biotech Files 2nd Quarter 2007 10QSB and Announces Unaudited Quarterly Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/22/2014)... , Dec. 22, 2014   Synthetic ... developer of pathogen-specific therapies for serious infections ... the microbiome, today announced positive topline safety ... clinical trial of SYN-004, the Company,s investigational ... Clostridium difficile (C. difficile) infection, ...
(Date:12/22/2014)... 22, 2014  Alternative Energy & Environmental Solutions, ... signed a letter of intent to acquire BioTechPharma ... patented a nanotechnology-based development platform used to create ... rapid on-site collection and testing to identify infectious ... in an immediate, non-invasive and cost-effective manner. ...
(Date:12/22/2014)... , Dec. 22, 2014  ( www.competitivehealth.com ) ... an online medical bill review and advocacy service, has ... the FREE WellCard Savings discount health services marketplace. ... that was more than they expected to pay. As ... health care costs, WellCard Savings is pleased to offer ...
(Date:12/22/2014)... 22, 2014 ITRA Global, one of ... of commercial real estate, has further expanded its global ... Perth and Brisbane, Western Australia, reports Mylinda Vick, CCIM, ... ITRA Global / ACORPP (Australian Corporate Property and ... company providing property services to a wide range of ...
Breaking Biology Technology:Synthetic Biologics Announces Positive Topline Results from Phase 1a Trial of SYN-004 for the Prevention of C. difficile Infection 2Synthetic Biologics Announces Positive Topline Results from Phase 1a Trial of SYN-004 for the Prevention of C. difficile Infection 3Synthetic Biologics Announces Positive Topline Results from Phase 1a Trial of SYN-004 for the Prevention of C. difficile Infection 4Synthetic Biologics Announces Positive Topline Results from Phase 1a Trial of SYN-004 for the Prevention of C. difficile Infection 5ALNE Announces Intention To Acquire BioTechPharma 2WellCard Savings Announces CoPatient Medical Bill Review Service for Members 2ITRA Global Continues International Expansion in Perth and Brisbane, Australia 2
... Biologics, Inc.  (NYSE Amex: SYN ), a ... for serious illnesses, announced today that Jeff Riley, the ... Capital Partners 24th Annual Growth Stock Conference. The conference ... Carlton in Dana Point, CA. Mr. Riley will present ...
... and LONGNAN CITY, China, March 6, 2012   Apexigen, ... Duyiwei Biological Pharmaceutical Co., Ltd. (GDBP), which is ... that they entered into a collaboration to grant ... commercialize APX004 in China.   APX004 is a humanized ...
... ORLANDO, Fla., March 6, 2012 CSL Behring announced ... Esterase Inhibitor (Human) within six hours of the onset of ... symptom relief than later treatment, according to data presented at ... Annual Meeting. While HAE patients treated within six hours of ...
Cached Biology Technology:Synthetic Biologics to Present at ROTH Annual Growth Stock Conference 2Apexigen and Shanghai Duyiwei Biotechnology Co. Ltd Sign a License and Collaboration Agreement to Develop and Commercialize APX004 2Apexigen and Shanghai Duyiwei Biotechnology Co. Ltd Sign a License and Collaboration Agreement to Develop and Commercialize APX004 3CSL Behring Study Confirms Early Treatment with Berinert® Provides Faster Resolution of Acute Hereditary Angioedema Symptoms 2CSL Behring Study Confirms Early Treatment with Berinert® Provides Faster Resolution of Acute Hereditary Angioedema Symptoms 3CSL Behring Study Confirms Early Treatment with Berinert® Provides Faster Resolution of Acute Hereditary Angioedema Symptoms 4
(Date:12/15/2014)... Research and Markets ( http://www.researchandmarkets.com/research/87pph8/global_facial ... "Global Facial Recognition Market 2015-2019" report to ... Facial recognition is a technology ... system measures the overall facial feature of a ... the distance between eyes. Facial recognition is used ...
(Date:12/10/2014)... You,ve been here before: you desperately need to sign into ... key or the answer to your secret question. What,s your ... Today, Hoyos Labs , a digital infrastructure security ... an end to the frustration that comes with usernames, passwords ... a user,s smartphone to acquire his or her biometrics to ...
(Date:12/10/2014)... 9, 2014     ...   Jifflenow, a ... solutions for business-to-business (B2B) events, today announced a ... mobile near-field communication (NFC), Bluetooth low energy (BLE), ... http://photos.prnewswire.com/prnh/20140612/691055) , Jifflenow will integrate its ...
Breaking Biology News(10 mins):Global Facial Recognition Market 2015-2019: Key Vendors are 3M Cogent, Cognitec Systems, NEC and Safran Group 2Global Facial Recognition Market 2015-2019: Key Vendors are 3M Cogent, Cognitec Systems, NEC and Safran Group 3The Password is Finally Dead: Launch of 1U Mobile App Eliminates Need for All Usernames and Passwords 2The Password is Finally Dead: Launch of 1U Mobile App Eliminates Need for All Usernames and Passwords 3Jifflenow And ITN International Bring Cutting-Edge Badge Scanning Technology To B2B Events 2Jifflenow And ITN International Bring Cutting-Edge Badge Scanning Technology To B2B Events 3
... -- Foiling exfiltration . . . Computer hackers ... developed by a team led by Justin Beaver of Oak ... attackers who breach a system,s defense have a distinct advantage ... window into potentially sensitive data and their true identity and ...
... Two new studies by researchers at the University of ... that eating rate plays in the amount of food ... faster than women, heavier people eat faster than slimmer ... grains, among other findings. Kathleen Melanson, URI associate ...
... of Mediterranean mountains could expand by up to 350% due to ... to cold and humid conditions, such as beech and Sylvester pines, ... possible in the 21st century according to a model created to ... Sistema Central and the Sistema Ibrico (Spain). A team led ...
Cached Biology News:Story tips from the US Department of Energy's Oak Ridge National Laboratory, November 2011 2Story tips from the US Department of Energy's Oak Ridge National Laboratory, November 2011 3Story tips from the US Department of Energy's Oak Ridge National Laboratory, November 2011 4Researcher provides further evidence that slow eating reduces food intake 2Holm oaks will gain ground in northern forests due to climate change 2
IKKbeta/IKK-2 Polyclonal Antibody 100 ug affinity purified rabbit polyclonal antibody. Reacts with human. Tested in Western blotting....
...
Request Info...
... The S.c. EasyComp Transformation Kit ... transformation-competent Saccharomyces cerevisiae cells. Advantages over ... spheroplast formation or LiCl methods include:- Cells ... than 30 minutes - Competent cell preparation ...
Biology Products: